Aviragen Therapeutics is Drug Discovery in United States that focus on protein inhibitor business. Founded in 1984. They cover business area such as Vaxart Inc, development, direct-act antiviral, infection, patient, three product candidate, vapendavir, an oral treatment, human rhinovirus, (HRV, moderate-to-severe asthmatic, an oral fusion protein inhibitor, prevention, respiratory syncytial virus, condyloma, human papillomavirus, US.
1984
( 40 years old in 2024 )
Protein Inhibitor
-
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009
United States
Private
Vaxart Incdevelopmentdirect-act antiviralinfectionpatientthree product candidatevapendaviran oral treatmenthuman rhinovirus(HRVmoderate-to-severe asthmatican oral fusion protein inhibitorpreventionrespiratory syncytial viruscondylomahuman papillomavirusUS
* We use standard office opening hours in near Aviragen Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Aviragen Therapeutics is Drug Discovery business from United States that founded in 1984 (40 years old in 2024), Aviragen Therapeutics business is focusing on Protein Inhibitor.
Aviragen Therapeutics headquarter office and corporate office address is located in 2500 Northwinds Parkway Suite 100 Alpharetta, GA 30009 United States.
Aviragen Therapeutics was founded in United States.
In 2024, Aviragen Therapeutics is currently focus on protein inhibitor sector.
Above is snippet of Google Trends for "protein inhibitor" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Aviragen Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
